Conclusions: Neoadjuvant BMS-813160/nivolumab/GnP was well tolerated and appears to achieve comparable ORR and resectability to historical data, however with prolonged PFS and OS in LA-PDAC patients, ...
Bristol Myers Squibb (BMS) has secured another win for Opdivo (nivolumab), becoming the only FDA-approved PD-1 inhibitor for resectable non-small cell lung cancer NSCLC in both a neoadjuvant-only ...
AZ is playing catch-up in neoadjuvant NSCLC with Bristol-Myers Squibb, which claimed an FDA approval for its PD-1 inhibitor Opdivo (nivolumab) in this indication in 2021 on the strength of the ...
3 The NESCIO trial is a randomized, open-label, three-arm phase II trial that aims to assess the efficacy and safety of neoadjuvant nivolumab alone or in combination in intermediate- to high-risk ...
4 Adjuvant nivolumab improved overall survival for patients with muscle invasive bladder cancer with (HR 0.74, 95% CI 0.53-1.03) and without prior neoadjuvant chemotherapy (HR 0.67, 95% CI 0.47-0.95): ...
CEL-SCI (CVM) announced new data has been published from its prior Phase 3 study of Multikine in newly diagnosed, treatment naive, resectable, ...
Exploratory post hoc analysis of molecular residual disease from the ADAURA trial of adjuvant osimertinib in patients with resected EGFR-mutated stage IB–IIIA non-small-cell lung cancer shows ...
Rescue therapies of relapsed/refractory (r/r) Hodgkin’s lymphoma (HL) in the third to sixth-line provide major, yet unresolved problems. The MEPED regimen includes nuclear receptor agonists such as ...
Selective avoidance of sentinel lymph node biopsy after neoadjuvant chemotherapy in patients with HER-2 positive/triple negative breast cancer: Prospective, multi-center, single-arm study (ASLAN).
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback